Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Glucose Evaluation Through Continuous Glucose Monitors in Polycystic Ovary Syndrome

NCT06050265
Conditions
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Dysglycemia, Insulin Resistance
Interventions
DEXCOM Continuous Glucose Monitor (CGM)
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Intermittent Hypoxia (IH) on Metabolism and Dysglycemia, in Overweight/Obese Persons SCI

NCT02973438
Conditions
Spinal Cord Injuries, Obesity, Insulin Resistance
Interventions
Intermittent Hypoxia (IH), SHAM
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Conditions
HIV/AIDS, Dysglycemia, Alcohol Use Disorder
Interventions
Exercise
Behavioral
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
New Orleans, Louisiana
Terminated Not applicable Interventional Results available

Glucose Time-In-Range Development Evaluation

NCT03670017
Conditions
ICU, Dysglycemia
Interventions
OptiScanner® 5000 Glucose Monitoring System
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Dysglycemia
Interventions
Continuous Glucose Monitor
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 50 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Diabetes Mellitus
Interventions
The Omnipod 5/Horizon HCL system
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Stanford, California • Atlanta, Georgia • Charlottesville, Virginia
Conditions
Cystic Fibrosis Related Diabetes, Cystic Fibrosis (CF), Abnormal Glucose Tolerance
Interventions
Verapamil Hydrochloride
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Conditions
Cystic Fibrosis, Cystic Fibrosis-related Diabetes, Cystic Fibrosis With Intestinal Manifestations
Interventions
Low Glycemic Load Diet
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Conditions
Type 1 Diabetes (T1D)
Interventions
Golimumab, Placebo (matching golimumab)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Years to 44 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Gestational Diabetes Mellitus, Hypertension in Pregnancy, Dysglycemia
Interventions
OB Provider Clinical Decision Support (CDS), Patient Education (OB Visit), Text messaging, Patient Outreach, Primary Care Provider Clinical Decision Support (CDS), Patient Education (Primary Care Visit)
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Chicago, Illinois
Active, not recruiting Phase 4 Interventional

Teplizumab in Pediatric Stage 2 Type 1 Diabetes

NCT05757713
Conditions
Diabetes Mellitus, Type 1
Interventions
teplizumab
Biological
Lead sponsor
Sanofi
Industry
Eligibility
0 Years to 7 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 7 more
Completed Not applicable Interventional Accepts healthy volunteers

Type 2 Diabetes and the Brain in Adolescents

NCT03461510
Conditions
Type 2 Diabetes Mellitus, Obesity, Pediatric Obesity, Insulin Resistance, Dysglycemia, Hyperglycemia
Interventions
Hyperglycemic clamp, Hyperinsulinemic Euglycemic clamp
Procedure
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 18 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Dysglycemia, Obesity
Interventions
Cinnamon, placebo
Dietary Supplement · Other
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
20 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Hemodialysis, Diabete Mellitus, Continuous Glucose Monitoring
Interventions
Continuous glucose monitoring (CGM), Usual care (Self-monitored blood glucose)
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 99 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Orange, California
Completed Not applicable Interventional Results available

Postpartum Continuous Glucose Monitoring (CGM) Study

NCT05714761
Conditions
Gestational Diabetes
Interventions
Dexcom glucose sensor
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Type2 Diabetes, Type 2 Diabetes Mellitus in Obese, Dysglycemia, Microvascular Complications, Brain Structure, Obesity, Childhood, Diabetes in Adolescence, Inflammation, Insulin Resistance, Overweight, Childhood, Cognitive Decline
Interventions
Observational
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 17 Years
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
St Louis, Missouri • Pittsburgh, Pennsylvania
Conditions
Cystic Fibrosis
Interventions
Sitagliptin
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 20 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Gestational Diabetes
Interventions
Continuous glucose monitoring for 14 days using the Freestyle LibrePro by Abbott
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Dysglycemia
Interventions
Dexcom G6 CGM
Device
Lead sponsor
DexCom, Inc.
Industry
Eligibility
21 Years to 110 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Not listed Not applicable Interventional Accepts healthy volunteers

Trial of Early Initiation of CGM-Guided Insulin Therapy in Stage 2 T1D

NCT04335513
Conditions
Type 1 Diabetes, Prediabetic State, Dysglycemia, Autoimmune Diabetes
Interventions
Early CGM-guided education and initiation of insulin therapy., Usual care: glucometer surveillance and basic education.
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Years to 20 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Nonalcoholic Steatohepatitis
Interventions
Placebo, ARI-3037MO
Drug
Lead sponsor
Arisaph Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
AID system with Remote Real-Time CGM, Standard of Care Insulin Therapy + CGM
Device · Combination Product
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
3
States / cities
Stanford, California • Atlanta, Georgia • Charlottesville, Virginia
Completed Phase 2 Interventional Results available

Metabolic Effects of Betaine Supplementation

NCT01950039
Conditions
Obesity, Dysglycemia
Interventions
Betaine, Placebo
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
21 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts